penny stock manipulation is the last thing this company needs unless you are in it for a quick trade. if that's the case then move along, this is not the company you are looking for. :-)
just to clarify, I am long the stock, for a looooooong time, but not BS'ing anyone on any ridiculous price targets
gee how about $20, $50 or even a $100!!!
Why do you ridiculous pumpers make this #$%$ up? When this gets approved and you start to see some sales data, then you can make an educated guess as to what valuation this company could garner and then you can speculate on stock price. Anything else is just a bunch of irresponsible cheerleading sure to doom anyone that listens to your drivel.
This is great news from the FDA!!
In closing it appears that we successfully completed an FDA inspection of our facilities in Medford this
week to review our procedures, processes and quality systems. The inspection was conducted under the
guidance of a baseline compliance work program for medical device level II. As the inspector was
wrapping up the review, he stated his audit findings look that we are fully compliant and he did not see
INVO Bioscience hopes to have the device on sale in the US by the end of this year. It is seeking a partner for a European launch.
British doctors raised safety concerns, including the potential for infection.
Professor Simon Fishel, managing director of the CARE Fertility group of clinics, cautioned that it will be impossible to check the embryos for defects when they are hidden away in the device. He added that it will ‘offer options for some’.
Dr Geeta Nargund, medical director of the Create fertility clinic in London’s Harley Street, said: ‘I welcome any development with the potential to reduce the cost of IVF.
We need to do more research to assess the impact on cost reduction and success of the method.’
It seems strange that they would raise an issue re: infections.at this point unless they don't have access to the results of the various trials that have been done over the last few years. Also re: cost reduction and the success of the method....
All of this should be available, I don't see why they would have to study this further?
there are many here that have been long this stock for several years. INVO has plugged along during this time hanging on to their hard work and furthering progress around the world while always eyeing the final prize, FDA approval in the United States.
Now that the trials in Texas have closed and data from those trials is being pubished, it seems the end is near and FDA approval is so close we can taste it.
There are two things that always tip you off, those are volume and price .
At first I thought you may be attempting to pump this as the report was last published 2010 and updated in 2011
First received: January 27, 2010
Last updated: February 6, 2011
Last verified: February 2011
We all know there is alot of old data on IVOB as they have been through a ridiculously long process to bring the INVOcell device to market but now I'm thinking we may finally have the goose that laid the golden egg.
If this was just published (10/31/14) on the Clinical Trial site, does this indicate FDA approval is imminent?
Another poster (stkwhizguru333) had indicated the ASRM has adopted the INVOcell as the new low cost alternative but they have not provided any reference for the claim.
"stkwhizguru333 • Oct 30, 2014 3:10 PM
ASRM has adopted the INVOcell as the new low cost alternative to IVF, having their endorsement is very important in this industry"
thought maybe it was more pumping but maybe there is some truth to it.
I would rather see it in print than just believe an anonymous internet post.
I agree, this should not have been posted but I'm curious as to the date of this email.
Why would the "FDA review protocolos now before running them" if the trials have already been done?
Novel IVF Technology: Safe and Effective, May Cut Costs
Conference Report | October 30, 2014 | ASRM 2014, IVF, Infertility, ObGyn Technology, Pregnancy and Birth
By Joelle Klein
An alternative technology to incubating embryos in a laboratory during an IVF (in vitro fertilization) cycle, with and without ICSI (intracytoplasmic sperm injection), has been found to be safe and effective and may reduce the high price tag of IVF.
At the 70th Annual Meeting of the American Society for Reproductive Medicine in Honolulu, HI, two studies were presented demonstrating that the use of the INVOcell vaginal culture device to incubate embryos resulted in embryos that were of comparable quality and pregnancy rates as those that were cultured in laboratory incubators.
“In vitro fertilization is the most effective treatment for infertility and the only one that is suitable for many. IVF is also resource intensive and its expense can put it out of reach of many patients who would benefit from it,” noted Charles Coddington, MD, President of the Society for Assisted Reproductive Technology.
In one study –A Randomized Prospective Controlled Trial Confirms the Safety and Efficacy of Extended Intravaginal Culture of Embryos with INVOcell Compared to Laboratory Incubators -- at the Center for Assisted Reproduction in Bedford, TX, 33 women between the ages of 18 and 38 undergoing IVF were randomly divided into two groups. One group’s embryos were incubated in the INVOcell device and the other group’s embryos were cultured in a laboratory.
After egg retrieval, each patient’s eggs were conventionally co-incubated with sperm for two to four hours. Then, up to 10 eggs were placed in the INVOcell device or moved to a laboratory incubator. After five days of culture, patients from both groups had one or two embryos transferred to their uteruses. Ten of the 16 women from the incubator culture group and 10 of the 17 women from the INVOcell group reported ongoing pregnancies.